Drug survival of infliximab and adalimumab in inflammatory bowel disease
- 21 October 2020
- journal article
- letter
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 42 (6) , 1521-1523
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Comparison of drug survival between infliximab and adalimumab in inflammatory bowel diseaseInternational Journal of Clinical Pharmacy, 2020
- Usefulness of population pharmacokinetics to optimize the dosage regimen of infliximab in inflammatory bowel disease patientsRevista Española de Enfermedades Digestivas, 2020
- Management of Anti‐drug Antibodies to Biologic Medications in Children With Inflammatory Bowel DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2019
- Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2019
- Letter: infliximab concentrations during induction therapy—one size does not fit allAlimentary Pharmacology & Therapeutics, 2018
- American Gastroenterological Association Institute Guideline on Therapeutic Drug Monitoring in Inflammatory Bowel DiseaseGastroenterology, 2017
- Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel DiseasesClinical Gastroenterology and Hepatology, 2016
- Systematic review: predicting and optimising response to anti‐TNF therapy in Crohn's disease – algorithm for practical managementAlimentary Pharmacology & Therapeutics, 2015
- Comparative Efficacy of Biologic Therapy in Biologic-Naïve Patients With Crohn Disease: A Systematic Review and Network Meta-analysisMayo Clinic Proceedings, 2014
- Antibody Response to Infliximab and its Impact on Pharmacokinetics can be TransientAmerican Journal of Gastroenterology, 2013